Practical Dermatology

11/19/2025

🔎 📊DRIVEN BY ITCH: A new pre-proof in JAAD shows that both itch and lesion severity independently predict biologic treatment initiation in patients with moderate-to-severe atopic dermatitis (AD).

Read more ➡️ https://ow.ly/hkMZ50Xu7nM

11/18/2025

📰 🩺 NEWS: Arcutis Biotherapeutics, Inc. announced that its supplemental New Drug Application (sNDA) for ZORYVE® ( ) cream 0.3% in children ages 2 to 5 with plaque has been accepted by the FDA. If approved, it would be the first topical PDE4 inhibitor for this age group.

Read more ➡️ https://ow.ly/ji2Z50XtOHp

11/17/2025

📢📊NEW TRALOKINUMAB DATA: Tralokinumab maintained significant efficacy through 32 weeks in adults with moderate-to-severe hand AD in the phase 3b ADHAND trial, addressing what the manufacturer LEO Pharma called one of AD’s most burdensome manifestations.

Read more ➡️ https://ow.ly/V3ZX50Xtbph

LEO Pharma has announced positive 32-week topline results from its ADHAND trial, a phase 3b study evaluating tralokinumab in adults with...

11/16/2025

IMPROVING CARE OPTIONS FOR CTCL: In this episode of C-Suite Chats, Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma and efforts to address those issues.

📺 Watch the episode ➡️ https://ow.ly/c7wc50XrZOf

Greg Palko, Vice President, North America, and Oncology Franchise Head for Kyowa Kirin, discusses the challenges posed by cutaneous T-cell lymphoma...

11/14/2025

📢 🧴 The INTEGUMENT-INFANT study of roflumilast cream 0.05% in infants with mild to moderate AD has completed enrollment, according to an announcement from Arcutis. Results are expected in early 2026.

Read more ➡️ https://ow.ly/RCua50XrZ9b

11/13/2025

🚨 📊 DO ANTIBIOTICS DISRUPT BIOLOGICS IN PsO? A brief report published online in JAMA Dermatology indicates systemic antibiotic use is associated with shorter persistence of biologic therapies in psoriasis. The dose-response effect suggests gut dysbiosis may play a role, according to the authors.

Read more ➡️ https://ow.ly/BwBB50XrbyM



Facebook
Can antibiotics shorten the effectiveness of biologics in psoriasis treatment? A French national study says yes—especially with repeated use. The findings point to gut microbiota disruption as a possible mechanism. Read the latest from JAMA Dermatology.

X / Twitter
🚨 Biologics less durable in psoriasis patients exposed to antibiotics, French study finds. Repeated courses = higher risk of discontinuation. Gut dysbiosis may be the link.

A new study says YES—with repeated antibiotic use linked to earlier biologic dropout. Could gut health be the missing link?
🧬
🧪 Source: JAMA Dermatology, Oct 2023

11/12/2025

🆕📊 REMIX-1/-2 UPDATE: Recently presented pooled data from the REMIX-1/-2 studies shows remibrutinib delivering rapid efficacy for chronic spontaneous urticaria (CSU) patients not responding to H₁-antihistamines. Topline results include favorable safety and a >70% symptom reduction at week 52.

Read more ➡️ https://ow.ly/tKLP50XqCSC

11/11/2025

🔎📊 GOOD NEWS FOR PEMPHIGUS PATIENTS: A new study using data from over 120 million U.S. EHRs finds no increased psychiatric risk in patients with pemphigus, challenging prior assumptions about mental health burden in autoimmune blistering disease. 🧠✨

Read more ➡️ https://ow.ly/fiRf50XqbGT

11/10/2025

🔎📊 STUDY SUPPORTS ENDOTHELIAL BARRIER THEORY: New evidence from a retrospective analysis of over 20 million US patients suggests seborrheic dermatitis is strongly linked to a range of systemic inflammatory diseases like rosacea, IBS, and celiac disease.

Read more ➡️ https://ow.ly/6xNM50XpCJV

11/07/2025

📢👨‍⚕️🚫 FDA ISSUES WARNINGS ON BOTULINUM TOXINS: The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded botulinum toxin products for cosmetic and medical use. The enforcement action follows reports of adverse events, including symptoms consistent with botulism, linked to these unauthorized products.

Read more ➡️ https://ow.ly/2cM550XoBrx

The US Food and Drug Administration (FDA) has issued 18 warning letters to website operators illegally marketing unapproved and misbranded...

11/06/2025

📢 🇬🇧 DELGOCITINIB ACCESS EXPANDED: The National Institute for Health and Care Excellence (NICE) has recommended reimbursement of delgocitinib cream for adult patients with moderate to severe chronic hand eczema (CHE) in England and Wales. Citing data from the DELTA trials, the decision expands the options for patients with limited response to corticosteroids and underscores the need for equitable assessment across diverse skin tones.

Read more ➡️ https://ow.ly/CRiE50Xo5lw

11/05/2025

📰 NEWS: Galderma’s Restylane Lyft just became the first HA filler in the U.S. to be FDA-approved for use in the chin, midface, hands, and facial folds. Backed by 12-month clinical trial data and high patient satisfaction, this expanded indication offers aesthetic practices new options for lower-face contouring.